CTXR — Citius Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $105.77m
- $86.02m
- 29
- 39
- 46
- 32
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 15.6 | 17.7 | 23.4 | 33.3 | 33.1 |
Operating Profit | -15.6 | -17.7 | -23.4 | -33.3 | -33.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -15.6 | -17.5 | -23.1 | -33.1 | -32 |
Provision for Income Taxes | |||||
Net Income After Taxes | -15.6 | -17.5 | -23.1 | -33.6 | -32.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -15.6 | -17.5 | -23.1 | -33.6 | -32.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -15.6 | -17.5 | -24.5 | -33.6 | -33.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.772 | -0.448 | -0.227 | -0.23 | -0.238 |